Transepidermal water loss (TEWL) and corneometry with hydrogel vehicle in the treatment of atopic dermatitis: a randomized, investigator-blind pilot study.
Transepidermal water loss (TEWL) and corneometry with hydrogel vehicle in the treatment of atopic dermatitis: a randomized, investigator-blind pilot study.
复制标题
水凝胶载体治疗特应性皮炎的经表皮失水 (TEWL) 和角质测量：一项随机、研究者盲法试点研究。
DOI：
--
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
L. Kircik
中科院分区：
文献类型：
--
作者：
L. Kircik
特应性皮炎(AD)的一个特征是表皮屏障的破坏，表现为皮肤水份的减少和经皮水分损失(TEWL)的增加。皮肤科治疗的新配方可以提高患者的满意度和依从性，并可能保护和增强表皮屏障功能。开展了一项单中心、研究者盲法、随机、分体探索性研究，以评估水基水凝胶载体的水化和屏障保护效果。受试者(n=20)，在基线水平上患有轻中度疾病，使用水凝胶载体或保湿乳液(Eucerin Lotion®，Biersdorf，Inc.)以一种分体的方式进行两周。角膜测量仪和TEWL测量是在基线和第二周进行的。与保湿乳液对照组相比，水凝胶载体在皮肤水分方面的改善具有统计学意义。水凝胶在TEWL中没有统计学上的显著变化，而对照洗剂增加了TEWL。这项初步研究的数据表明，水基水凝胶载体改善了皮肤的水分，不会进一步损害表皮屏障功能，这表明它是轻中度特应性皮炎患者的合适载体选择。
Disruption of the epidermal barrier, as indicated by a reduction in skin hydration and an increase in transepidermal water loss (TEWL) is a feature of atopic dermatitis (AD). Novel formulations of dermatologic therapies may enhance patient satisfaction and adherence and may possibly preserve and enhance epidermal barrier function. A single-center, investigator-blinded, randomized, split-body exploratory study was undertaken to assess the hydrating and barrier preserving effects of a water-based hydrogel vehicle. Subjects (n=20) with mild to moderate disease at baseline applied hydrogel vehicle or a moisturizing lotion (Eucerin Lotion®, Beiersdorf, Inc.) in a split-body fashion for two weeks. Corneometry and TEWL measurements were taken at baseline and week 2. Hydrogel vehicle produced a statistically significant improvement in skin hydration from baseline, as compared to a moisturizing lotion control. Hydrogel produced no statistically significant change in TEWL, while comparator lotion increased TEWL. Data from this pilot study indicate that the water-based hydrogel vehicle improves skin hydration and does not further impair epidermal barrier function, suggesting that it is an appropriate vehicle choice for patients with mild-to-moderate atopic dermatitis.